下載本文檔
版權說明:本文檔由用戶提供并上傳,收益歸屬內容提供方,若內容存在侵權,請進行舉報或認領
文檔簡介
本文格式為Word版,下載可任意編輯——歐蘭寧奧氮平片說明書1?EfficacywasestablishedwithSymbyax(olanzapineandHIGHLIGHTSOFPRESCRIBINGINATIONfluoxetineincombination)inadults;refertotheproductlabelThesehighlightsdonotincludealltheinationneededtouseforSymbyax.ZYPREXAsafelyandeffectively.SeefullprescribinginationforZYPREXA.DOSAGEANDADMINISTRATIONZYPREXA(olanzapine)TabletforOraluseZYPREXAZYDIS(olanzapine)Tablet,OrallyDisintegratingforOraluseZYPREXAIntraMuscular(olanzapine)Injection,Powder,ForSolutionforIntramuscularuseInitialU.S.Approval:1996WARNING:INCREASEDMORTALITYINELDERLYPATIENTSWITHDEMENTIA-RELATEDPSYCHOSISSeefullprescribinginationforcompleteboxedwarning.?Elderlypatientswithdementia-relatedpsychosistreatedwithantipsychoticdrugsareatanincreasedriskofdeath.ZYPREXAisnotapprovedforthetreatmentofpatientswithdementia-relatedpsychosis.(5.1,5.12,17.2)WhenusingZYPREXAandfluoxetineincombination,alsorefertotheBoxedWarningsectionofthepackageinsertforSymbyax.RECENTMAJORCHANGESWarningsandPrecautions:MetabolicChanges(5.4)12/2022OrthostaticHypotension(5.6)MM/YYYYHyperprolactinemia(5.13)12/2022INDICATIONSANDUSAGEZYPREXA?(olanzapine)isanatypicalantipsychoticindicated:Asoralulationforthe:?Treatmentofschizophrenia.(1.1)?Adults:Efficacywasestablishedinthreeclinicaltrialsinpatientswithschizophrenia:two6-weektrialsandonemaintenancetrial.(14.1)?Adolescents(ages13-17):Efficacywasestablishedinone6-weektrialinpatientswithschizophrenia(14.1).Theincreasedpotential(inadolescentscomparedwithadults)forweightgainanddyslipidemiamayleadclinicianstoconsiderprescribingotherdrugsfirstinadolescents.(1.1)?AcutetreatmentofmanicormixedepisodesassociatedwithbipolarIdisorderandmaintenancetreatmentofbipolarIdisorder.(1.2)?Adults:EfficacywasestablishedinthreeclinicaltrialsinpatientswithmanicormixedepisodesofbipolarIdisorder:two3-to4-weektrialsandonemaintenancetrial.(14.2)?Adolescents(ages13-17):Efficacywasestablishedinone3-weektrialinpatientswithmanicormixedepisodesassociatedwithbipolarIdisorder(14.2).Theincreasedpotential(inadolescentscomparedwithadults)forweightgainanddyslipidemiamayleadclinicianstoconsiderprescribingotherdrugsfirstinadolescents.(1.2)?MedicationtherapyforpediatricpatientswithschizophreniaorbipolarIdisordershouldbeundertakenonlyafterathoroughdiagnosticuationandwithcarefulconsiderationofthepotentialrisks.(1.3)?AdjuncttovalproateorlithiuminthetreatmentofmanicormixedepisodesassociatedwithbipolarIdisorder.(1.2)?Efficacywasestablishedintwo6-weekclinicaltrialsinadults(14.2).Maintenanceefficacyhasnotbeensystematicallyuated.AsZYPREXAIntraMuscularforthe:?TreatmentofacuteagitationassociatedwithschizophreniaandbipolarImania.(1.4)?Efficacywasestablishedinthree1-daytrialsinadults.(14.3)AsZYPREXAandFluoxetineinCombinationforthe:?TreatmentofdepressiveepisodesassociatedwithbipolarIdisorder.(1.5)?EfficacywasestablishedwithSymbyax(olanzapineandfluoxetineincombination);refertotheproductlabelforSymbyax.?Treatmentoftreatmentresistantdepression.(1.6)Schizophreniainadults(2.1)Oral:Startat5-10mgoncedaily;Target:10mg/daywithinseveraldaysSchizophreniainadolescents(2.1)Oral:Startat2.5-5mgoncedaily;Target:10mg/dayBipolarIDisorder(manicormixedepisodes)inadults(2.2)Oral:Startat10or15mgoncedailyBipolarIDisorder(manicormixedepisodes)inadolescents(2.2)Oral:Startat2.5-5mgoncedaily;Target:10mg/dayBipolarIDisorder(manicormixedepisodes)withlithiumorvalproateinadults(2.2)Oral:Startat10mgoncedailyAgitationassociatedwithSchizophreniaandBipolarIManiainadults(2.4)IM:10mg(5mgor7.5mgwhenclinicallywarranted)Assessfororthostatichypotensionpriortosubsequentdosing(max.3doses2-4hrsapart)DepressiveEpisodesassociatedwithBipolarIDisorderinadults(2.5)Oralincombinationwithfluoxetine:Startat5mgoforalolanzapineand20mgoffluoxetineoncedailyDepressiveEpisodesassociatedwithBipolarIDisorderinchildrenandadolescents(2.5)Oralincombinationwithfluoxetine:Startat2.5mgoforalolanzapineand20mgoffluoxetineoncedailyTreatmentResistantDepressioninadults(2.6)Oralincombina
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯系上傳者。文件的所有權益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網頁內容里面會有圖紙預覽,若沒有圖紙預覽就沒有圖紙。
- 4. 未經權益所有人同意不得將文件中的內容挪作商業(yè)或盈利用途。
- 5. 人人文庫網僅提供信息存儲空間,僅對用戶上傳內容的表現方式做保護處理,對用戶上傳分享的文檔內容本身不做任何修改或編輯,并不能對任何下載內容負責。
- 6. 下載文件中如有侵權或不適當內容,請與我們聯系,我們立即糾正。
- 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 2025年咸寧貨運從業(yè)資格證考試模擬
- 2025年云浮貨運從業(yè)資格仿真考題
- 2025年雙鴨山貨運從業(yè)資格證考試模擬
- 【大學課件】信息通信專業(yè):應用層組播技術的研究
- 《數字電路測試》課件
- 《銀行贏在管理培訓》課件
- 2025燈具購貨合同范本
- 2025服裝品牌區(qū)域代理合同范例
- 垃圾處理的成本與效益
- 2025版權登記合同許可合同
- 7750BRAS維護與配置(SR功能篇)
- 二級供應商管理
- 《投資理財》課件
- 《公寓消防培訓資料》課件
- 2024-2025學年人教版七年級數學上冊期末檢測試卷
- 2024中國融通集團北京企業(yè)管理共享中心社會招聘筆試備考試題及答案解析
- 《中國傳統(tǒng)文化》課件模板(六套)
- 鍋爐使用單位鍋爐安全日管控、周排查、月調度制度
- 《信息安全風險管理》課件
- 第24課《寓言四則》說課稿 2024-2025學年統(tǒng)編版語文七年級上冊
- 色卡-CBCC中國建筑標準色卡(千色卡1026色)
評論
0/150
提交評論